Drug intelligence / Profile preview

AVG-004

Development stage: Preclinical
Lead developer: AlveoGene
Modality: Gene Therapies
Administration: Inhalation

Overview

**AVG-004** is an AlveoGene preclinical multi-transgene lentiviral-vector gene therapy being advanced for idiopathic pulmonary fibrosis. The program uses AlveoGene's InGenuiTy platform and is intended to address disease mechanisms underlying pulmonary fibrosis; the specific therapeutic transgenes and molecular targets have not been publicly disclosed. AlveoGene lists AVG-004 at the candidate-selection stage.

Beyond the preview

Go deeper on AVG-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVG-004.

Explore the full profile